EP
NBIX icon

Edgestream Partners’s Neurocrine Biosciences NBIX Stock Holding History

Edgestream Partners’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-50,587
Closed -$6.66M – 1083
2026
Q1 		$6.66M Buy
50,587
+28,979
+134% +$3.85M 0.22% 147
2025
Q4 		$3.06M Buy
21,608
+17,649
+446% +$2.56M 0.09% 418
2025
Q3 		$556K Sell
3,959
-69,645
-95% -$9.44M 0.02% 718
2025
Q2 		$9.25M Buy
+73,604
New +$8.44M 0.26% 91
2025
Q1 		– Sell
-12,574
Closed -$1.72M – 970
2024
Q4 		$1.72M Buy
12,574
+7,308
+139% +$904K 0.07% 432
2024
Q3 		$607K Sell
5,266
-38,928
-88% -$5.34M 0.03% 667
2024
Q2 		$6.08M Buy
44,194
+20,189
+84% +$2.77M 0.29% 76
2024
Q1 		$3.31M Buy
24,005
+10,002
+71% +$1.37M 0.17% 208
2023
Q4 		$1.85M Buy
14,003
+11,957
+584% +$1.38M 0.13% 265
2023
Q3 		$230K Sell
2,046
-10,657
-84% -$1.12M 0.02% 768
2023
Q2 		$1.2M Sell
12,703
-24,569
-66% -$2.4M 0.11% 316
2023
Q1 		$3.77M Buy
37,272
+19,118
+105% +$1.99M 0.42% 44
2022
Q4 		$2.17M Buy
18,154
+9,365
+107% +$1.1M 0.24% 136
2022
Q3 		$933K Buy
8,789
+3,620
+70% +$367K 0.07% 282
2022
Q2 		$504K Sell
5,169
-20,954
-80% -$1.93M 0.04% 407
2022
Q1 		$2.45M Sell
26,123
-19,933
-43% -$1.69M 0.2% 176
2021
Q4 		$3.92M Buy
+46,056
New +$4.24M 0.24% 129
2021
Q2 		– Sell
-8,857
Closed -$861K – 512
2021
Q1 		$861K Buy
+8,857
New +$929K 0.05% 305

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Edgestream Partners's NBIX Position: Q2 2026 in Review

Edgestream Partners sold out of Neurocrine Biosciences (NBIX) in Q2 2026, closing a stake of 50,587 shares — an estimated $6.66M sold.

Edgestream Partners first reported a position in NBIX in Q1 2021 and held it in 18 quarters. The position peaked at $9.25M in Q2 2025. 771 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Edgestream Partners reported no remaining Neurocrine Biosciences position as of Q2 2026 after selling out during the quarter.
  • Edgestream Partners sold 50,587 Neurocrine Biosciences shares in Q2 2026, an estimated $6.66M.
  • Edgestream Partners first reported a position in Neurocrine Biosciences in Q1 2021 and held it in 18 quarters.
  • Edgestream Partners's Neurocrine Biosciences position peaked at $9.25M in Q2 2025.
  • 771 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Edgestream Partners's 13F filing for Q2 2026, filed 11 Aug 2026.